Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants - Wikidata - wikimedia - TriplyDB

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

http://www.wikidata.org/entity/Q24610169

about

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Combinatorial Versus Individual Gene Pharmacogenomic Testing in Mental Health: A Perspective on Context and Implications on Clinical Utility Economic evaluations of personalized medicine: existing challenges and current developments Serotonergic gene variation in substance use pharmacotherapy: a systematic review Pharmacogenetics and outcome with antipsychotic drugs Depression, antidepressants, and bone health in older adults: a systematic review CYP2D6 polymorphisms and their influence on risperidone treatment Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing Ethical and public policy challenges for pharmacogenomics Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy Distribution of CYP2D6 alleles and phenotypes in the Brazilian population Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial Pharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19.Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Implementation and utilization of genetic testing in personalized medicine.Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response Pharmacogenetics in clinical practice: how far have we come and where are we going?Pharmacogenetics in Jewish populations.Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy.Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.SNP genotyping using TaqMan technology: the CYP2D6*17 assay conundrum.Functional characterization of CYP2D6 enhancer polymorphisms EHR based Genetic Testing Knowledge Base (iGTKB) Development.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report.Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele.In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools.CYP2D6 copy number distribution in the US population.CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6 (*) 15 and (*) 35 Genotyping.Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.

P2860

Q24567778-11FEF33F-DAFD-40C9-B119-A4221C8622CA Q26775813-1DAD1EBD-A07B-4F73-9018-8FC9536362A9 Q26797183-40E963C6-C846-4405-B54C-262A811004EF Q26799093-7FF5BC51-5D8E-4E88-8182-585795998FA2 Q26852807-DDE693D4-7783-4854-A5E6-F91F4A839662 Q27010527-E46C579C-A53F-4590-A25F-2663CB76BAD8 Q28079227-EACDA897-61C7-4EC9-AB14-6AB0CF9F8A37 Q28079766-6E4E9FBF-AA5E-4F4A-B8F8-8C904B3F86C2 Q28083508-477370F5-6630-461D-BC19-ABB57708CC30 Q28392069-5A9D19F6-4D1C-4BC2-9AE2-FCE42C98E0CE Q28468503-132B7823-28D5-439C-BFCE-3A8D08337EB2 Q28543940-51028A35-B2D4-4A95-9D32-ABE9E89CEC51 Q28553076-F14A5D0F-B9DC-4EDD-9639-C76740160D24 Q30711413-B1BB6EB7-51E7-4846-B5D1-00C72664952C Q31058146-1A16478A-F83B-4137-BA33-B9C1797A5482 Q33435875-0A482B34-5649-44DB-BA33-4A7CCA626A84 Q33597438-0B0D0B9A-61C1-41D6-AA21-A121A8360EC6 Q33615625-EB207E77-C71E-49EC-9D81-51F7D1E15914 Q34138276-592DB0FE-2272-4FDC-B5D4-07131AEEC234 Q34147916-C75B3A24-7AD9-4913-82A4-BDC880D6EC36 Q34173696-97FCB2F4-FDA0-450C-A3B5-1BB8766C785B Q34343365-D1DE3068-6A70-4533-9A62-ECB35F57A9A0 Q34458720-1B9EFB3D-24EA-4A52-8A3F-289F1921B978 Q34879739-CAA89C9D-307D-41AA-A54C-2EE86E6936C3 Q34982153-C528B5C8-E3DC-46E3-BCFE-C656A1A48A35 Q35107992-C2BC2FEE-FE58-42D9-9B68-4CEBC688B575 Q35193678-E9FC2646-9016-408E-91EB-7139E6F70B9F Q35239357-C782BEA7-7E7B-4A6C-80CF-D68A54807319 Q35852441-BC1C73B8-F50D-4C81-9935-FEAEA9527007 Q35862776-AFD1FA99-21EE-40FF-95E8-D124B36B4F09 Q35897778-DD2A17A8-4196-42D6-9693-2B6D70429B0A Q35953819-128CD935-2FF1-4612-8E77-C091092CE080 Q35965584-64AE03AF-DDE2-40B7-B13C-C545C6EA3208 Q36166107-81F2F86B-0891-4DB5-99B8-3C89A11DF1F3 Q36240653-8D616B68-63B2-48BF-B85B-9988ECFB3FAA Q36243663-31D458F2-C359-4996-B471-36931C791FFD Q36274662-22DB457E-9B1D-48E6-AAF8-34E27E76C42D Q36440207-C337899F-92FC-41D2-84BF-A0E3E9EE4663 Q36454174-48D4D355-855E-42F0-99AF-70BBB7ED2D85 Q36508972-550EA548-CC68-478B-95B5-E570B8A4D68B

P2860

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

http://www.wikidata.org/entity/Q24610169

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@ast

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@en

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@nl

type

label

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@ast

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@en

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@nl

prefLabel

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@ast

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@en

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@nl

P1433

Q24610169-572D6F65-A9D8-4A34-80EB-123BC0C73117

P1476

Q24610169-350E6593-51D4-4FC7-B117-6D67F7BD0141

P2093

Q24610169-1F8DDC68-8C2A-494F-B26A-4D6661C15D50

Q24610169-56B5F5CE-406F-40AA-AFA4-23B5A700389C

Q24610169-61DADD3E-57D4-4EFB-9A95-6CF05DEA1985

Q24610169-67B8A661-B7DB-4C85-801D-C443078F20BA

Q24610169-77F7C7D8-EACC-49E0-9CF4-1E5845C790E4

Q24610169-874CEADC-5D22-4266-9ADF-8C1F3F027420

Q24610169-AD1FA594-8EBF-4DFA-8765-D43C80905393

Q24610169-BB757E18-A049-4543-86CB-327A7B4F2B90

Q24610169-C651C90C-1D47-472E-AEB8-431D5E13A417

Q24610169-DBA48EB0-FF54-40DE-BEA0-9B9E9F2FBDED

P2860

Q24610169-068874DF-3A3E-441D-A640-15B1D831B483

Q24610169-1839B13F-8910-4009-83EE-069FF346481C

Q24610169-1F9EC26D-1B5A-4D6B-96E2-8CB4416CDD16

Q24610169-23CA0440-425F-4584-9895-DC5BCE781888

Q24610169-3B637671-DC2B-434B-9712-0B74A8C95723

Q24610169-422283F8-F4E7-45F6-9150-CB7BD6264203

Q24610169-42E6DACA-BD45-441F-A0EB-3A7784DE268E

Q24610169-54B5290B-936C-4204-AE0B-B09D25BAEBBB

Q24610169-5DE43F87-485C-4985-9327-C77E39D6D1D1

Q24610169-630BB213-940E-4EAE-B930-CDE972F857CD

P2888

Q24610169-FEE46072-EFDD-4544-9D4A-430CA3B77F63

P304

Q24610169-201BA994-F236-40AA-9A2C-7715C593B192

P31

Q24610169-3D0F6CED-55B7-4D70-855E-91E86AD76E9D

P3181

Q24610169-B946D3EB-51F0-4200-8B3F-76E1DD494B4F

P356

Q24610169-44EA8D70-D211-41C7-A1DA-03636F0C588A

P407

Q24610169-C02CF4E7-F74A-4E0A-95AC-545A551D2425

P433

Q24610169-C748781A-8A6C-4165-A9B5-873478B29ADD

P478

Q24610169-75FEFB3A-2D63-4542-94BB-BCF721F0D3D7

P577

Q24610169-D6961B01-A18B-4A96-B639-10395F3F2562

P5875

Q24610169-7B2D6729-D36A-4D00-AD90-6F45D3E40A6E

P6179

Q24610169-187E2FDC-9C17-431F-99E4-9E749635AD55

P698

Q24610169-12BCEA46-B963-4AC4-9A57-D56D4DE20E79

P932

Q24610169-77FEB840-6A7B-47BD-BE3E-045739C03A36

P3181

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Clinical Pharmacogenetics Impl ...... g of tricyclic antidepressants

@en

P2093

A Gaedigk

http://www.w3.org/2001/XMLSchema#string

C F Thorn

http://www.w3.org/2001/XMLSchema#string

D J Müller

http://www.w3.org/2001/XMLSchema#string

E D Kharasch

http://www.w3.org/2001/XMLSchema#string

J C Stingl

http://www.w3.org/2001/XMLSchema#string

J J Swen

http://www.w3.org/2001/XMLSchema#string

J K Hicks

http://www.w3.org/2001/XMLSchema#string

K Sangkuhl

http://www.w3.org/2001/XMLSchema#string

T C Skaar

http://www.w3.org/2001/XMLSchema#string

V L Ellingrod

http://www.w3.org/2001/XMLSchema#string

P2860

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

Metabolism of tricyclic antidepressants.

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

The treatment of neuropathic pain: antidepressants and opioids.

Pharmacogenetics: from bench to byte--an update of guidelines.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.

Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.

Pharmacologic management of neuropathic pain: evidence-based recommendations.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

P2888

P304

402-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1352854

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/CLPT.2013.2

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236042729

http://www.w3.org/2001/XMLSchema#string

P6179

1024615269

http://www.w3.org/2001/XMLSchema#string

P698

23486447

http://www.w3.org/2001/XMLSchema#string

P932

3689226

http://www.w3.org/2001/XMLSchema#string